Herantis Pharma Plc HRTIS
OMXHEX · Finland · Health Technology
€1.39-0.03 (-2.11%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Espoo, Finland, August 20, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 1H 2026 report. The full report is attached to this release and is also available on the Company’s website: www.herantis.com. Antti Vuolanto, CEO of Herantis Pharma, commented: “The first half of 2026 has been highly productive for Herantis. We reported Phase 1b biomarker data confirming biol
Brings more than 25 years of global drug development, regulatory and strategic leadership experience successfully guiding innovative therapies from clinical development through regulatory approval and commercialization Espoo, Finland, 25 June 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the appointment of Dr Juha Savola, MD, PhD as Chief Medical Officer (CMO).
FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo, Finland, 2 June 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today provides an update on preparations for the Phase 2a proof-of-concept efficacy study of HER-096, its lead candidate for the treatmen
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.